Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Control of graft-versus-host disease with rabbit anti-thymocyte globulin, rituximab, and bortezomib in TCRαβ/CD19-depleted graft transplantation for leukemia in children: a single-center retrospective analysis of two GVHD-prophylaxis regimens. 31680369 2020
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 AlteredExpression disease BEFREE The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. 30733273 2019
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use. 30622115 2019
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE We performed a preclinical validation using a model of CD33<sup>+</sup> AML, and generated iC9 CAR T-cells co-expressing a CAR targeting the AML-associated antigen CD33 and a selectable marker (ΔCD19).ΔCD19 selected (sel.) iC9-CAR.CD33 T-cells were effective in controlling leukemia growth in vitro, and could be partially eliminated (76%) using a chemical inducer of dimerization that activates iC9. 30539529 2019
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE CD19-targeted CAR-T is an effective modality in treating refractory B-cell malignancies including leukemia and lymphoma. 28762313 2019
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE CD19 CAR T cell product and disease attributes predict leukemia remission durability. 30860496 2019
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma. 30828333 2019
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Return of CD19+ leukemia was associated with loss of CAR T-cell function, whereas CD19- leukemia was associated with continued CAR T-cell function. 31738832 2019
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE These results are the first to establish the clinical activity of a CD22-CAR in B-ALL, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses. 29155426 2018
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19<sup>-</sup> leukemia that aberrantly expressed the anti-CD19 CAR. 30275568 2018
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. 30097433 2018
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE The clinical use of genetically modified T-cell therapies has led to unprecedented response rates in leukemia and lymphoma patients treated with anti-CD19 chimeric antigen receptor (CAR)-T. Despite this clinical success, FDA-approved T-cell therapies are currently limited to B-cell malignancies, and challenges remain with managing cytokine-related toxicities. 30479831 2018
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. 29743205 2018
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE 1928zT2 T cells exhibited enhanced effector function against CD19+ leukemic cells in vitro and in a xenograft model of human extramedullary leukemia. 29458388 2018
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE The remarkable clinical response rates achieved by adoptive transfer of T cells that target CD19 in patients with leukemia and lymphoma have led to a growing number of clinical trials exploring CAR T-cell therapy for solid tumors. 29107016 2018
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. 28515942 2017
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 AlteredExpression disease BEFREE During this treatment, the leukemia lost CD19 expression as well as nearly all other B-cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype. 28453885 2017
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE The treatment of leukemia/lymphoma by chimeric antigen receptor (CAR) redirected T cells with specificity for CD19 induced complete remissions in the majority of patients, with a realistic hope for cure. 29207878 2017
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. 29451276 2017
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE CAR T cells targeting CD19 have emerged as a remarkable T cell-based therapy for the successful treatment of certain types of leukemia and lymphomas. 28708956 2017
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 AlteredExpression disease BEFREE We retrospectively analyzed 65 patients with refractory/relapsed (r/r) ALL who were treated with blinatumomab for predictors of leukemia response as well as clinical patterns of relapse and resistance with particular focus on downregulation of CD19 expression and extramedullary disease (EM-ALL). 28494518 2017
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Novel therapies with chimeric antigen receptor (CAR)-transduced T cells (TCs) sparked new hope for patients with relapsed or refractory CD19-positive leukemia or lymphoma even after stem cell therapies. 27479233 2016
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Infusion of CD19-ENG T cells resulted in regression of leukemia or lymphoma in xenograft models and a survival advantage in comparison to control mice. 27255991 2016
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE Such incongruity was also observed in t(4;11) patients in whom leukemia evaded CD19-directed therapy by undergoing myeloid-lineage switch. 27846391 2016
Entrez Id: 930
Gene Symbol: CD19
CD19
0.100 Biomarker disease BEFREE In this study, we compared CD19 bispecific T-cell engager (BiTE)-transferred T cells that had been transfected by RNA electroporation with CD19 CAR RNA-transferred T cells both in vitro and in an aggressive Nalm6 leukemia mouse model. 27258611 2016